Medical Device Regulation (MDR)

Medical Device Regulation (MDR) — Regulation 2017/745 (EU) on medical devices

The Ger­man equi­va­lent for the term Me­di­cal De­vice Re­gu­la­ti­on (MDR) is “Me­di­cal De­vice Re­gu­la­ti­on”. The Eu­ro­pean Uni­on (EU) Re­gu­la­ti­on 2017/745 will be­co­me bin­ding th­roug­hout Eu­ro­pe on May 26, 2021. In this ar­tic­le you will find in­for­ma­ti­on on con­tent and im­ple­men­ta­ti­on re­gu­la­ti­ons for the me­di­cal tech­no­lo­gy industry.

EU regulation tailored to medical technology

Al­re­a­dy on April 5, 2017, the “Re­gu­la­ti­on (EU) 2017/745 of the Eu­ro­pean Par­lia­ment and of the Coun­cil on me­di­cal pro­ducts” en­te­red into force. It re­places the pre­vious­ly va­lid “Di­rec­ti­ve 93/42/EEC on me­di­cal de­vices”. In con­cre­te terms, this me­ans for you in the me­di­cal tech­no­lo­gy sec­tor that EU Re­gu­la­ti­on 2017/745 su­per­se­des the fol­lo­wing ear­lier directives:

  • Me­di­cal De­vice Di­rec­ti­ve 93/42/EEC (MDD);
  • Di­rec­ti­ve 90/385/EEC, ac­ti­ve im­plan­ta­ble me­di­cal de­vices — Ac­ti­ve Im­lan­ta­ble Me­di­cal De­vices (AIMDD)

The EU bo­dies opted for a se­pa­ra­te re­gu­la­ti­on with re­gard to Di­rec­ti­ve 98/79/EC on in vi­tro dia­gno­stic me­di­cal de­vices (IVD). This gui­de­line did not find its way into the me­di­cal de­vice re­gu­la­ti­on. It will be re­pla­ced by the se­pa­ra­te­ly worded EU re­gu­la­ti­on “In-Vi­tro Dia­gno­stic Me­di­cal De­vices Re­gu­la­ti­on 2017/746 (IVDR).

Discover the right software for MDR compliance

Sup­port and sim­pli­fy the crea­ti­on and up­dating of your tech­ni­cal do­cu­men­ta­ti­on with our pro­cess-ori­en­ted dos­sier ma­nage­ment, e.g. in the con­text of the re­qui­re­ments of the Me­di­cal De­vice Re­gu­la­ti­on (MDR). Com­pli­ant with ISO 13485 MPG and Me­di­cal De­vice Re­gu­la­ti­on (MDR).

Live insight into the GxP-compliant document management system of Digital Life Sciences

Mandatory throughout Europe as of May 26, 2021

In con­trast to the su­per­se­ded di­rec­ti­ve, the EU Parliament’s new re­gu­la­ti­on has gai­ned an in­ter­na­tio­nal pro­fi­le. Its bin­ding va­li­di­ty ex­tends to all EU mem­ber sta­tes from the key date of May 26, 2021. It should be no­ted here that as of Oc­to­ber 2019, no na­tio­nal le­gal acts have yet been ad­opted by the in­di­vi­du­al mem­ber sta­tes. This also ap­pli­es to Ger­man spe­ci­fics, re­qui­re­ments and pe­nal pro­vi­si­ons to be en­ac­ted. A cor­re­spon­ding draft for a Ger­man im­ple­men­ting law does exist. Nevert­hel­ess, the Fe­de­ral Mi­nis­try of He­alth an­ti­ci­pa­tes tran­si­ti­on periods.

Ac­cor­ding to the pre­sent text of the law, a tran­si­ti­on pe­ri­od of th­ree ye­ars (05/26/17 — 05/25/21*) ap­pli­es du­ring im­ple­men­ta­ti­on. Af­ter the dead­line at the la­test, you as a ma­nu­fac­tu­rer are ob­li­ged to sub­mit an MDR cer­ti­fi­ca­te. This is the only way you are al­lo­wed to launch a pro­duct to the mar­ket for the first time.

*In the wake of the COVID 19 pan­de­mic, the ef­fec­ti­ve date of the re­gu­la­ti­on was de­lay­ed to May 26, 2021 

Aim and necessity of the new EU regulation

Es­sen­ti­al­ly, the new re­gu­la­ti­on aims to op­ti­mi­se and stan­dar­di­se the mar­ket launch of me­di­cal tech­no­lo­gy pro­ducts. The fo­cus is on the fac­tors of pro­duct safe­ty and pro­duct qua­li­ty.
For you as a mar­ket par­ti­ci­pant and user, the new EU re­gu­la­ti­on con­sists of a mix of fa­mi­li­ar con­tent from the pre­vious Di­rec­ti­ve 93/42/EEC and far-rea­ching new fea­tures. Among the es­sen­ti­al, sub­stan­ti­ve and pro­ce­du­ral con­tent for you and your in­dus­try are the fol­lo­wing con­tents of the Brussels Regulation:

Ru­les for the clas­si­fi­ca­ti­on of me­di­cal de­vices
New terms and ru­les lead to ch­an­ges in the as­sign­ment of exis­ting pro­ducts to par­ti­al­ly mo­di­fied pro­duct clas­ses. For ex­am­p­le, the pro­duct area of “stand-alo­ne” soft­ware is af­fec­ted by the­se changes.

Con­for­mi­ty eva­lua­ti­on pro­ce­du­re
Fol­lo­wing the clas­si­fi­ca­ti­on ru­les, the con­for­mi­ty as­sess­ment pro­ce­du­re now also va­ries de­pen­ding on the class.

Tech­ni­cal Documentation/Document Ma­nage­ment Sys­tem
The tech­ni­cal do­cu­men­ta­ti­on ac­cor­ding to Me­di­cal De­vice Re­gu­la­ti­on pro­ves to be much more de­tail­ed. The ad­van­ta­ges of con­trol and do­cu­men­ta­ti­on for com­pa­nies be­co­me clear when the new un­der­ly­ing ta­bu­lar sche­me is ex­ami­ned in de­tail. The sub­di­vi­si­on into in­di­vi­du­al ca­te­go­ries in a di­rect link with the as­so­cia­ted de­tail­ed re­qui­re­ments forms the ba­sis for a de­tail­ed tech­ni­cal documentation.

Cli­ni­cal evaluations/clinical ve­ri­fi­ca­ti­ons
Si­gni­fi­cant­ly in­creased re­qui­re­ments cha­rac­te­ri­ze this ac­tion item. This ap­pli­es in par­ti­cu­lar to high-risk pro­duct groups.

Com­pa­ny responsibility/safety of­fi­cer
A si­gni­fi­cant ch­an­ge for your com­pa­ny re­sults from the re­qui­re­ment of the EU bo­dies for a re­spon­si­ble per­son who is re­spon­si­ble for re­gu­la­to­ry com­pli­ance in their organization.

Qua­li­ty ma­nage­ment
The FDA Me­di­cal De­vice 21 CFR 820 (FDA = U.S. Food and Drug Ad­mi­nis­tra­ti­on) sti­pu­la­tes the re­qui­re­ments for ma­nage­ment sys­tems of me­di­cal de­vice ma­nu­fac­tu­r­ers. In this func­tion, the 21 CFR 820 de­vice is the equi­va­lent of ISO 13485. The core re­qui­re­ment is that pro­cess in­s­truc­tions such as Do­cu­ment Con­trol, Pro­cu­re­ment, De­ve­lo­p­ment and Pro­duc­tion are do­cu­men­ted and im­ple­men­ted analogously.

Mar­ket sur­veil­lan­ce me­cha­nisms
In par­ti­cu­lar, the man­da­to­ry use of the EUDAMED da­ta­ba­se pro­vi­des grea­ter trans­pa­ren­cy. It is available to both the pu­blic and di­rect com­pe­ti­tors as an in­for­ma­ti­on me­di­um. The cha­rac­te­ristics of each me­di­cal de­vice are map­ped by me­ans of ap­pro­pria­te links. Sup­p­ly chain tracea­bi­li­ty is also possible.

Ways to comply with the Medical Device Regulation

To fa­sci­li­ta­te ti­me­ly com­pli­ance with the new re­gu­la­ti­on, you are cal­led upon to act, if you hold a re­spon­si­ble po­si­ti­on in your com­pa­ny. A co­her­ent plan for the tran­si­ti­on of your com­pa­ny to the Me­di­cal De­vice Re­gu­la­ti­on, both in terms of time and con­tent, is a pre­re­qui­si­te for your suc­cess. High prio­ri­ty should be gi­ven to the life cy­cles of your me­di­cal de­vice port­fo­lio. Exis­ting MDD cer­ti­fi­ca­ti­ons will lose their va­li­di­ty on May 26, 2024, ac­cor­ding to EU re­gu­la­ti­ons. Plea­se note in your plan­ning that your pro­ducts al­re­a­dy cer­ti­fied ac­cor­ding to MDD must also com­ple­te the new con­for­mi­ty pro­cess to be es­tab­lished ac­cor­ding to MDR. A “grand­fa­the­ring” is not guaranteed.

Du­ring the tran­si­ti­on pha­se, you are par­ti­cu­lar­ly chal­len­ged in your func­tion as a ma­nu­fac­tu­rer or pro­vi­der. The hig­hest prio­ri­ty is to de­si­gna­te and trai­ning the per­son re­spon­si­ble for re­gu­la­to­ry com­pli­ance in your fa­ci­li­ty (MDR Ar­tic­le 15). Up­dates to in­ter­nal qua­li­ty assu­rance pro­ce­du­res, do­cu­men­ta­ti­on, and mo­di­fied pro­duct clas­si­fi­ca­ti­on are mandatory.

Against this back­ground, the fol­lo­wing stan­dar­di­zed pro­ce­du­re ac­cor­ding to the fol­lo­wing 4 points is recommended:

  • Im­ple­men­ta­ti­on of the con­for­mi­ty eva­lua­ti­on re­la­ted to the product
  • Com­ple­ting a de­cla­ra­ti­on of conformity
  • “CE” mar­king of the products
  • Re­gis­tra­ti­on of com­pa­ny and pro­ducts in the EUDAMED database.

Conclusion and criticism of the new regulation

With MDR , the EU of­fi­ci­als have set out to crea­te a con­tem­po­ra­ry, stan­dar­di­sed so­lu­ti­on for qua­li­ty ma­nage­ment and the mar­ket re­lease of me­di­cal de­vices. Gre­at at­ten­ti­on is paid to the qua­li­ty and safe­ty of pro­ducts. Per­haps you also be­long to the group of small and me­di­um-si­zed com­pa­nies in the me­di­cal tech­no­lo­gy sec­tor that fear over-re­gu­la­ti­on by the ex­ten­si­ve set of re­gu­la­ti­ons and ad­di­tio­nal au­di­ting bodies?

In par­ti­cu­lar, the eva­lua­ti­on of com­pli­ance by the “com­pli­ance ma­na­ger” to be re­crui­ted is li­kely to be­co­me a staf­fing pro­blem du­ring the start-up pha­se. In a case of hard­ship, a shorta­ge of cer­ti­fied au­di­tors could de­lay the cer­ti­fi­ca­ti­on nee­ded for mar­ket re­lease. Me­di­cal tech­no­lo­gy in­dus­try as­so­cia­ti­ons ex­press fe­ars that a bot­t­len­eck in cer­ti­fi­ca­ti­ons could have a ne­ga­ti­ve im­pact on the mar­ket launch of in­no­va­ti­ve and mar­ke­ta­ble products.

Start your digital transformation in terms of MDR compliance with our powerful, modular software solution

Share now!

Subscribe to the newsletter

You want to stay up to date? Then subscribe to our newsletter.

EU GMP Guidelines Chapter 4

De­fi­ni­ti­on of the term (“What is Chap­ter 4 of the EU GMP Gui­de?”) Chap­ter 4 of the EU GMP Gui­de fo­cu­ses on do­cu­men­ta­ti­on and re­cords in

Enterprise Content Management System (ECM)

De­fi­ni­ti­on of the term (“What is ECM?”)  En­ter­pri­se Con­tent Ma­nage­ment, of­ten ab­bre­via­ted as ECM, is a ro­bust and in­te­gra­ted set of pro­ces­ses and tech­no­lo­gies de­si­gned to